Pfizer Clinical Trials: 3,933 Led Studies

Archive historyOct 2022 to Jun 2026

98 recorded changes across Pfizer trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 27 of these trials. One is shown below.

Completion date movePrimary completion moved 295 days laterNCT07013474 · recorded 1 Jun 2026

Track to read them

+94 more recorded changes · Track a drug to see every change the night it lands

Start tracking drugs

Most active programmes

The drugs appearing most often across Pfizer's recently active trials. Comparator arms are excluded.

Etrasimod7 trials
PF-086344047 trials
Rimegepant5 trials
PF-086539445 trials
PG44 trials
20-valent pneumococcal conjugate vaccine (20vPnC)4 trials

Upcoming readouts

Next primary completion dates among Pfizer's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Aug 2026MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multi…Phase 3
Oct 2026A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migrain…Phase 3
Nov 2026A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent …Phase 3
Dec 2026A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resista…Phase 3
Dec 2026A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria…Phase 2
Mar 2027A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lastin…Phase 2

Top therapeutic areas

Conditions studied most often across Pfizer's recently active trials.

Carcinoma, Non-Small-Cell Lung6 trials
COVID-195 trials
Colorectal Neoplasms5 trials
Obesity5 trials
Overweight5 trials
Pneumococcal Disease4 trials

Pfizer trials

The 50 most significant of Pfizer's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting PneumoniaNCT07251465Receipt of PCV20	—	Not yet scored	OngoingActive, not recruiting	846,279 est.	31 Jul 2026
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)NCT06152575Elranatamab	Phase 3	Locked · track to reveal	OngoingRecruiting	492 est.	30 Aug 2026
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07400679PF-08653944	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	54 est.	18 Sept 2026
A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.NCT06587035Somatrogon	—	Not yet scored	OngoingRecruiting	50 est.	21 Sept 2026
A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male AdultsNCT07508228Oral [14C]PF-07328948	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	8 est.	24 Sept 2026
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigraineNCT06616194Rimegepant	Phase 3	Locked · track to reveal	OngoingRecruiting	200 est.	8 Oct 2026
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662PF-07934040	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	64 est.	9 Oct 2026
BORLANDEvaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetNCT07235397ABRYSVO	—	Not yet scored	OngoingNot yet recruiting	1 est.	13 Nov 2026
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineNCT06641466Rimegepant	Phase 3	Locked · track to reveal	OngoingRecruiting	723 est.	29 Nov 2026
Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic CosmosNCT07673081	—	Not yet scored	OngoingNot yet recruiting	293,334 est.	30 Nov 2026
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779PF-06821497	Phase 3	Locked · track to reveal	OngoingRecruiting	900 est.	2 Dec 2026
B7981027A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711Ritlecitinib higher dose	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	208 est.	2 Dec 2026
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.NCT07219615Ritlecitinib 50 mg	Phase 2	Locked · track to reveal	OngoingRecruiting	200 est.	25 Dec 2026
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Avelumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	77 est.	31 Dec 2026
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFNCT07653100RSVpreF	Phase 3	Not yet scored	OngoingNot yet recruiting	540 est.	25 Jan 2027
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or ObesityNCT07508241PF-08653944	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	22 est.	27 Jan 2027
ATTRACTAbrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)NCT06353087	—	Not yet scored	OngoingActive, not recruiting	41 est.	30 Jan 2027
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.NCT07228390Ritlecitinib	Phase 2	Locked · track to reveal	OngoingRecruiting	240 est.	5 Mar 2027
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative InfectionsNCT05639647ATM-AVI	Phase 2	Locked · track to reveal	OngoingRecruiting	48 est.	31 Mar 2027
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisNCT04624230tofacitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	118 est.	14 Apr 2027
A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsNCT06524414PG4	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	605 est.	1 May 2027
A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632sigvotatug vedotin	Phase 1	Locked · track to reveal	OngoingRecruiting	1,006 est.	16 Jun 2027
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaNCT07660731PF-08103402	Phase 1	Not yet scored	OngoingRecruiting	139 est.	18 Jun 2027
Tranquillo 2A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2NCT06072183Ritlecitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	1,571 est.	30 Jul 2027
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130PF-07799544	Phase 1	Locked · track to reveal	OngoingRecruiting	124 est.	2 Aug 2027
SOLIS-1A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)NCT07575932PF-08653945	Phase 2	Locked · track to reveal	OngoingRecruiting	872 est.	4 Aug 2027
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver DiseaseNCT07677358Atirmociclib	Phase 1	Not yet scored	OngoingNot yet recruiting	28 est.	14 Aug 2027
VESPER-4Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850MET097	Phase 3	Locked · track to reveal	OngoingRecruiting	3,501 est.	21 Sept 2027
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedNCT07013474ibuzatrelvir	Phase 3	Locked · track to reveal	OngoingRecruiting	300 est.	27 Sept 2027
ENDEAVOUR-UCAn Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisNCT06398626Etrasimod	—	Not yet scored	OngoingRecruiting	300 est.	1 Oct 2027
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseaseNCT06679140ibuzatrelvir	Phase 3	Locked · track to reveal	OngoingRecruiting	2,330 est.	3 Oct 2027
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653PF-08653944	Phase 3	Locked · track to reveal	OngoingRecruiting	999 est.	12 Oct 2027
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.NCT07227012PF-08634404	Phase 1	Locked · track to reveal	OngoingRecruiting	138 est.	18 Oct 2027
A Study to Learn About How a New Pneumococcal Vaccine Works in AdultsNCT07086677PG4 vaccine in Buffer 1 with low dose PA-001	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	380 est.	21 Oct 2027
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerNCT07227415PF-08634404	Phase 1	Locked · track to reveal	OngoingRecruiting	224 est.	2 Nov 2027
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsNCT07660198PG4	Phase 3	Not yet scored	OngoingRecruiting	1,200 est.	2 Dec 2027
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerNCT07421700PF-08634404	Phase 1	Locked · track to reveal	OngoingRecruiting	132 est.	6 Dec 2027
ADAIRA Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.NCT05689151Abrocitinib	—	Not yet scored	OngoingRecruiting	183 est.	31 Dec 2027
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaNCT07685769Rimegepant 75 mg ODT	Phase 4	Not yet scored	OngoingNot yet recruiting	60 est.	11 Jan 2028
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatigueNCT06989437ponsegromab	Phase 2	Locked · track to reveal	OngoingRecruiting	982 est.	17 Jan 2028
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in TaiwanNCT07391761Non intervention	—	Not yet scored	OngoingActive, not recruiting	1 est.	31 Jan 2028
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight LossNCT07663630ponsegromab	Phase 1	Not yet scored	OngoingNot yet recruiting	80 est.	2 Feb 2028
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseNCT06866405RSVpreF	Phase 3	Locked · track to reveal	OngoingRecruiting	550 est.	24 Feb 2028
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Mervometostat (PF-06821497)	Phase 1	Locked · track to reveal	OngoingRecruiting	453 est.	20 Apr 2028
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701PF-07799933	Phase 1	Locked · track to reveal	OngoingRecruiting	267 est.	23 Apr 2028
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549PF-08653944	Phase 3	Locked · track to reveal	OngoingRecruiting	954 est.	4 May 2028
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineNCT07609914Rimegepant	Phase 4	Locked · track to reveal	OngoingRecruiting	400 est.	15 May 2028
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853Mevrometostat	Phase 3	Locked · track to reveal	OngoingRecruiting	1,000 est.	12 Sept 2028
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesNCT07160244Multivalent Group B streptococcus vaccine	Phase 3	Locked · track to reveal	OngoingRecruiting	6,000 est.	6 Nov 2028
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsNCT07573462PG4	Phase 3	Locked · track to reveal	OngoingRecruiting	2,400 est.	30 Dec 2028

View all trials3,933

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3RecruitingNCT06152575 ↗

Primary completion: Aug 2026; estimated
Enrollment: 492; estimated
Start: Feb 2024; Pfizer

Conditions

Multiple Myeloma

Interventions

Elranatamab
Elotuzumab
Pomalidomide
Dexamethasone
Bortezomib
Carfilzomib

Brief summary

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2025

Completion date move · 1

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

Phase 1Active, not recruitingNCT07400679 ↗

Primary completion: Sept 2026; estimated
Enrollment: 54; estimated
Start: Feb 2026; Pfizer

Conditions

Overweight
Obesity
Healthy

Interventions

PF-08653944

Brief summary

This study is being done to learn how the study medicine affects the body and how safe it is for people who take it. The researchers will look at a number of health tests, including blood tests such as calcitonin, amylase, and lipase, because similar medicines have sometimes caused changes in these tests. This study…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jun 2026

Enrollment change · 1

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1Active, not recruitingNCT06447662 ↗

Primary completion: Oct 2026; estimated
Enrollment: 64; estimated
Start: Jun 2024; Pfizer

Conditions

Carcinoma, Pancreatic Ductal
Colorectal Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions

PF-07934040
Gemcitabine
Nab-paclitaxel
Cetuximab
Fluorouracil
Oxaliplatin
Leucovorin
Bevacizumab

Brief summary

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Completion date move · 3

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

B7981027: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

Phase 3Active, not recruitingNCT07029711 ↗

Primary completion: Dec 2026; estimated
Enrollment: 208; estimated
Start: Jul 2025; Pfizer

Conditions

Severe Alopecia Areata

Interventions

Ritlecitinib higher dose
Ritlecitinib lower dose
Placebo

Brief summary

The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due to alopecia…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Sept 2025

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Phase 2RecruitingNCT07219615 ↗

Primary completion: Dec 2026; estimated
Enrollment: 200; estimated
Start: Oct 2025; Pfizer

Conditions

Chronic Spontaneous Urticaria

Interventions

Ritlecitinib 50 mg
Ritlecitinib 100 mg
Placebo - 50 mg
Placebo - 100 mg

Brief summary

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are used to stop the body's "allergy alarm system" from overreacting. Chronic spontaneous…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Dec 2025

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3Active, not recruitingNCT05059522 ↗

Primary completion: Dec 2026; estimated
Enrollment: 77; estimated
Start: Sept 2021; Pfizer

Conditions

Advanced Malignancies
NSCLC
Ovarian Cancer
Urothelial Cancer
Solid Tumors

Interventions

Avelumab
Lorlatanib
Talazoparib
Pemetrexed
Axitinib
CMP 001
Utomilumab
PF04518600

Brief summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jul 2024

Completion date move · 3

Enrollment change · 1

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

Phase 1Active, not recruitingNCT07508241 ↗

Primary completion: Jan 2027; estimated
Enrollment: 22; estimated
Start: Mar 2026; Pfizer

Conditions

Obesity
Overweight and/or Obesity
Overweight
Drug Interaction

Interventions

PF-08653944
Acetaminophen

Brief summary

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity. Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Phase 2RecruitingNCT05639647 ↗

Primary completion: Mar 2027; estimated
Enrollment: 48; estimated
Start: Apr 2023; Pfizer

Conditions

Gram-negative Bacterial Infections

Interventions

ATM-AVI
BAT

Brief summary

The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants. The study is seeking participants who are: * 9 months to less than 18 years of age * Hospitalized *…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jul 2025

Completion date move · 3

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Phase 3Active, not recruitingNCT04624230 ↗

Primary completion: Apr 2027; estimated
Enrollment: 118; estimated
Start: Aug 2021; Pfizer

Conditions

Ulcerative Colitis

Interventions

tofacitinib

Brief summary

This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Mar 2026

Completion date move · 3

Status change · 1

Enrollment change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

Phase 2Active, not recruitingNCT06524414 ↗

Primary completion: May 2027; estimated
Enrollment: 605; estimated
Start: Jul 2024; Pfizer

Conditions

Pneumococcal Disease

Interventions

PG4
20-valent pneumococcal conjugate vaccine (20vPnC)
15-valent pneumococcal conjugate vaccine (PCV15)

Brief summary

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine. To ensure that the new…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Oct 2025

Enrollment change · 3

Status change · 1

Completion date move · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1RecruitingNCT04389632 ↗

Primary completion: Jun 2027; estimated
Enrollment: 1,006; estimated
Start: Jun 2020; Seagen, a wholly owned subsidiary of Pfizer

Conditions

Carcinoma, Non-Small Cell Lung
Squamous Cell Carcinoma of Head and Neck
HER2 Negative Breast Neoplasms
Esophageal Squamous Cell Carcinoma
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Ovarian Neoplasms
Cutaneous Squamous Cell Cancer

Interventions

sigvotatug vedotin
pembrolizumab
cisplatin
carboplatin

Brief summary

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Aug 2025

Enrollment change · 4

Completion date move · 3

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

Phase 1RecruitingNCT07660731 ↗

Primary completion: Jun 2027; estimated
Enrollment: 139; estimated
Start: Jun 2026; Pfizer

Conditions

Healthy Volunteer Study
Healthy Adults
Healthy Participants
Asthma

Interventions

PF-08103402
Placebo
Midazolam

Brief summary

The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people. For Parts A, B, C, D and F, the study is seeking participants…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Tranquillo 2: A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

Phase 3Active, not recruitingNCT06072183 ↗

Primary completion: Jul 2027; estimated
Enrollment: 1,571; estimated
Start: Nov 2023; Pfizer

Conditions

Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo

Interventions

Ritlecitinib
Ritlecitinib
Placebo

Brief summary

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body such…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Sept 2025

Enrollment change · 2

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Phase 1RecruitingNCT05538130 ↗

Primary completion: Aug 2027; estimated
Enrollment: 124; estimated
Start: Nov 2022; Pfizer

Conditions

Melanoma
Glioma
Thyroid Cancer
Non-Small Cell Lung Cancer
Malignant Neoplasms
Brain Neoplasms
Advanced or Metastatic Solid Tumors
HGG

Interventions

PF-07799544
PF-07799933

Brief summary

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with…

Full record on ClinicalTrials.gov ↗

Change timeline

12 recorded · latest 1 May 2026

Completion date move · 11

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

Phase 1Not yet recruitingNCT07677358 ↗

Primary completion: Aug 2027; estimated
Enrollment: 28; estimated
Start: Jul 2026; Pfizer

Conditions

Hepatic Impairment
Healthy, Hepatic Insufficiency
Healthy Adults

Interventions

Atirmociclib

Brief summary

The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health. The study is seeking participants who are: * Aged 18 years or older * Have a BMI of 17.5 to 40 kg/m2, and body weight more than 50 kg. * Have normal…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Phase 3RecruitingNCT07013474 ↗

Primary completion: Sept 2027; estimated
Enrollment: 300; estimated
Start: Jul 2025; Pfizer

Conditions

COVID-19 Infection

Interventions

ibuzatrelvir
remdesivir
placebo for ibuzatrelvir
placebo for remdesivir

Brief summary

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jun 2026

Completion date move · 1

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Phase 3RecruitingNCT06679140 ↗

Primary completion: Oct 2027; estimated
Enrollment: 2,330; estimated
Start: Dec 2024; Pfizer

Conditions

COVID-19 SARS-CoV-2 Infection

Interventions

ibuzatrelvir
placebo

Brief summary

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2026

Completion date move · 1

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Phase 3RecruitingNCT07400653 ↗

Primary completion: Oct 2027; estimated
Enrollment: 999; estimated
Start: Feb 2026; Pfizer

Conditions

Obesity
Overweight and/or Obesity
Overweight
Diabetes, Type 2
Type 2 Diabetes

Interventions

PF-08653944
Placebo

Brief summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in the blood. The…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Phase 1RecruitingNCT07227012 ↗

Primary completion: Oct 2027; estimated
Enrollment: 138; estimated
Start: Dec 2025; Pfizer

Conditions

Carcinoma, Hepatocellular
Hepatocellular Cancer
Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Liver Neoplasms
Advanced Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma

Interventions

PF-08634404
Ipilimumab

Brief summary

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

Phase 1Active, not recruitingNCT07086677 ↗

Primary completion: Oct 2027; estimated
Enrollment: 380; estimated
Start: Jul 2025; Pfizer

Conditions

Streptococcus Pneumoniae

Interventions

PG4 vaccine in Buffer 1 with low dose PA-001
PG4 in Buffer 1 with low dose PA-002
PG4 in Buffer 1 with high dose PA-001
PG4 vaccine in Buffer 1 with high dose PA-002
PG4 vaccine in Buffer 2
20-valent pneumococcal conjugate vaccine
Saline injection

Brief summary

The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Status change · 2

Enrollment change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Phase 1RecruitingNCT07227415 ↗

Primary completion: Nov 2027; estimated
Enrollment: 224; estimated
Start: Feb 2026; Pfizer

Conditions

Carcinoma, Renal Cell
Advanced Renal Cell Carcinoma
Renal Cancer
Renal Neoplasm
Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell Metastasis

Interventions

PF-08634404
Ipilimumab
Axitinib

Brief summary

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine,…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1RecruitingNCT07421700 ↗

Primary completion: Dec 2027; estimated
Enrollment: 132; estimated
Start: Mar 2026; Pfizer

Conditions

Urothelial Cancer
Advanced/Metastatic Urothelial Cancer
Urothelial Carcinoma

Interventions

PF-08634404
Enfortumab Vedotin

Brief summary

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Phase 2RecruitingNCT06989437 ↗

Primary completion: Jan 2028; estimated
Enrollment: 982; estimated
Start: Oct 2025; Pfizer

Conditions

Cachexia
Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

ponsegromab
placebo

Brief summary

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Nov 2025

Completion date move · 2

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1RecruitingNCT03460977 ↗

Primary completion: Apr 2028; estimated
Enrollment: 453; estimated
Start: Apr 2018; Pfizer

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)
Small Cell Lung Cancer (SCLC)
Follicular Lymphoma (FL)

Interventions

Mervometostat (PF-06821497)
Enzalutamide
Itraconazole

Brief summary

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2…

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 1 Dec 2025

Completion date move · 7

Enrollment change · 3

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1RecruitingNCT05355701 ↗

Primary completion: Apr 2028; estimated
Enrollment: 267; estimated
Start: Jul 2022; Pfizer

Conditions

Melanoma
Non-Small-Cell Lung Cancer
Thyroid Cancer
Glioma
Advanced Colorectal Cancer (Part 1)

Interventions

PF-07799933
binimetinib
cetuximab
midazolam
fluorouracil
leucovorin
oxaliplatin

Brief summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of…

Full record on ClinicalTrials.gov ↗

Change timeline

16 recorded · latest 1 May 2026

Completion date move · 14

Enrollment change · 1

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Phase 3RecruitingNCT07028853 ↗

Primary completion: Sept 2028; estimated
Enrollment: 1,000; estimated
Start: Sept 2025; Pfizer

Conditions

Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Hormone Sensitive Prostate Cancer
Prostate Cancer
Cancer of the Prostate

Interventions

Mevrometostat
Placebo
Enzalutamide

Brief summary

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track Pfizer drugs to see every change the night it lands.

Start tracking drugs